[1]袁金玲,陈新建,廖凯,等.昼夜节律分子BMAL1通过调节免疫细胞毒性促进骨肉瘤的预后[J].第三军医大学学报,2020,42(18):1787-1794.
 YUAN Jinling,CHEN Xinjian,LIAO Kai,et al.Circadian rhythms molecule BMAL1 promotes the prognosis of osteosarcoma via regulating immune cell cytotoxicity[J].J Third Mil Med Univ,2020,42(18):1787-1794.
点击复制

昼夜节律分子BMAL1通过调节免疫细胞毒性促进骨肉瘤的预后(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第18期
页码:
1787-1794
栏目:
基础医学
出版日期:
2020-09-30

文章信息/Info

Title:
Circadian rhythms molecule BMAL1 promotes the prognosis of osteosarcoma via regulating immune cell cytotoxicity
作者:
袁金玲陈新建廖凯彭虹艳李梨平张树菊
中南大学湘雅三医院检验科;南部战区空军医院血管内科;长沙血液中心;湖南省儿童医院儿科医学研究所
Author(s):
YUAN Jinling CHEN Xinjian LIAO Kai PENG Hongyan LI Liping ZHANG Shuju

Department of Clinical Laboratory, the Third Xiangya Hospital of Central South University, Changsha, Hunan Province, 410000; 2Department of Cardiovascular Diseases, Airforce Hospital of Southern Theater Command, Guangzhou, Guangdong Province, 510062; 3Changsha Blood Center, Changsha, Hunan Province, 410000; 4Hunan Children’s Research Institute, Hunan Provincial Children’s Hospital, Changsha, Hunan Province, 410007, China
 

关键词:
骨肉瘤昼夜节律BMAL1骨肉瘤预后细胞毒性  
Keywords:
osteosarcoma circadian rhythms BMAL1 osteosarcoma prognosis cytotoxicity
分类号:
R394.3;R730.23;R738.1
文献标志码:
A
摘要:

目的探讨核心节律分子在骨肉瘤预后中的作用及可能机制。方法在骨肉瘤细胞中过表达节律基因BMAL1, qRTPCR检测BMAL1基因的表达;克隆形成实验和Transwell实验检测细胞的克隆形成和侵袭能力;骨肉瘤细胞与外周血单个核淋巴细胞(peripheral blood mononuclear cell,PBMCs)体外共培养后,钙黄素染色法检测PBMCs对骨肉瘤细胞的直接杀伤作用,流式细胞术检测PBMCs中CD8+ T和NK细胞脱颗粒(CD107a蛋白表达)的影响。结果BMAL1 mRNA高表达的骨肉瘤患者的生存时间明显高于低表达组(P<0.000 1)。BMAL1过表达对U2OS细胞的侵袭和克隆形成无显著影响,但相较于对照组而言,过表达BMAL1的U2OS在体外与外周血单核血细胞(PBMCs)共培养4 h,其细胞死亡明显增加[PBMCs∶U2OS细胞为5∶1时,对照组和BMAL1组分别为(73.33±0.67)%和(81.00±0.58)%, P<0.01;PBMCs∶U2OS细胞为10∶1时,对照组和BMAL1组分别为(76.67±0.33)%
和(82.67±1.86)%,P<0.01]。过表达BMAL1的骨肉瘤细胞组与PBMCs共培养后,T细胞和NK细胞CD107a表达差异无统计学意义(E∶T=5∶1, CD3+ CD56- T 细胞, P=0.46; CD3- CD56+ NK 细胞, P=0.96; E∶T=10∶1, CD3+ CD56- T 细胞, P=0.93; CD3-CD56+ NK 细胞, P=0.21)。结论骨肉瘤细胞BMAL1表达水平与骨肉瘤患者预后呈正相关,其机制主要是通过增加免疫细胞对其免疫监视作用,而非通过影响骨肉瘤细胞的克隆形成能力和侵袭。

Abstract:

ObjectiveTo investigate the role and possible mechanism of the core rhythm molecule BMAL1 in the prognosis of osteosarcoma (OS). MethodsAfter BMAL1 was overexpressed in U2OS cells by Lipofectamine3000, the expression of BMAL1 was detected with qRTPCR, and the clone formation and invasion ability of the overexpressed cells were observed with clonogenic assay and Transwell assay. Then, the BMAL1 overexpressed U2OS cells or the cells with control vector transfection were cocultured with peripheral blood mononuclear cells (PBMCs), the direct killing effects of PBMCs on U2OS cells was observed with Calcein AM staining, and the CD107a expression by CD8+ T and NK cells was measured with flow cytometry. ResultsThe OS patients with higher BMAL1 mRNA level had significantly longer survival time when compared with those with lower expression (P<0.001). BMAL1 overexpression had no obvious effects on the invasion and clone formation of U2OS cells. However, cell death was significantly increased in BMAL1 overexpressed U2OS cells than the control vector transfected U2OS cells when cocultured with PBMCs in vitro [PBMCs∶U2OS cells=5∶1, (81.00±0.58)% vs (73.33±0.67)%, P<0.01; PBMCs∶U2OS cells=10∶1, (82.67±1.86)% vs (76.67±0.33)%, P<0.01]. There was no significant difference in the expression level of CD107a between T cells and NK cells in the BMAL1 overexpressed U2OS cells than the control vector transfected U2OS cells when cocultured with PBMCs (E∶T=5∶1, CD3+ CD56- T cells, P=0.46, CD3-CD56+ NK cells, P=0.96; E∶T=10∶1, CD3+ CD56- T cells, P=0.93; CD3-CD56+ NK cells, P=0.21). ConclusionThe expression level of BMAL1 is positively correlated with the prognosis of OS patients, which might be mainly due to the enhanced immunological surveillance, but not by affecting the ability of invasion and clone formation of OS cells.

参考文献/References:

[1]BIERMANN J S, ADKINS D R, AGULNIK M, et al. Bone cancer[J]. J Natl Compr Canc Netw, 2013, 11(6): 688-723. DOI: 10.6004/jnccn.2013.0088.

[2]NG A J, MUTSAERS A J, BAKER E K, et al. Genetically engineered mouse models and human osteosarcoma[J]. Clin Sarcoma Res, 2012, 2(1): 1-14. DOI: 10.1186/20453329219.

[3]ALLISON D C, CARNEY S, AHLMANN E R, et al. A metaanalysis of osteosarcoma outcomes in the modern medical era[J]. Sarcoma, 2012, 2012: 704872. DOI: 10.1155/2012/704872.

[4]LONGHI A, ERRANI C, DE PAOLIS M, et al. Primary bone osteosarcoma in the pediatric age: state of the art[J]. Cancer Treat Rev, 2006, 32(6): 423-436. DOI: 10.1016/j.ctrv.2006.05.005.

[5]KAGER L, ZOUBEK A, POTSCHGER U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2003, 21(10): 2011-2018. DOI: 10.1200/JCO.2003.08.132.

[6]KAGER L, TAMAMYAN G, BIELACK S. Novel insights and therapeutic interventions for pediatric osteosarcoma[J]. Futur Oncol, 2017, 13(4): 357-368. DOI: 10.2217/fon 20160261.

[7]JONES K B. Osteosarcoma genesis: modeling cancer initiation in the mouse[J]. Sarcoma, 2011, 2011: 694136. DOI: 10.1155/2011/694136.

[8]LUSSIER D M, JOHNSON J L, HINGORANI P,et al. Combination immunotherapy with αCTLA4 and αPDL1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma[J]. J Immunother Cancer, 2015, 3: 21. DOI: 10.1186/s404250150067z. eCollection 2015.

[9]HEYMANN M F, SCHIAVONE K, HEYMANN D.Bone sarcomas in the immunotherapy era[J]. Br J Pharmacol,2020,23.DOI: 10.1111/bph.14999.

[10]BASS J, LAZAR M A. Circadian time signatures of fitness and disease[J]. Science, 2016, 354(6315): 994-999. DOI: 10.1126/science.aah4965.

[11]PANDA S. Circadian physiology of metabolism[J]. Science, 2016, 354(6315): 1008-1015. DOI: 10.1126/science. aah4967.

[12]FU L, PELICANO H, LIU J S, et al. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo[J]. Cell,2002,111(1): 41-50. DOI: 10.1016/s00928674(02)009613.

[13]LOGAN R W, ZHANG C Q, MURUGAN S, et al. Chronic shiftlag alters the circadian clock of NK cells and promotes lung cancer growth in rats[J]. J Immunol, 2012, 188(6): 2583-2591. DOI: 10.4049/jimmunol.1102715.

[14]WU Y C, TAO B R, ZHANG T Y, et al. Pancancer analysis reveals disrupted circadian clock associates with T cell exhaustion[J]. Front Immunol, 2019, 10: 2451. DOI: 10.3389/fimmu.2019.02451.

[15]KIM E, JUNG S, PARK W S, et al.Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data[J]. BMC Cancer,2019 ,19(1): 302. DOI: 10.1186/s128850195475x.

[16]ZHANG S J, ZHANG J M, DENG Z Y,et al.Circadian clock components RORα and BMAL1 mediate the antiproliferative effect of MLN4924 in osteosarcoma cells[J]. Oncotarget, 2016,7(40): 66087-66099. DOI: 10.18632/oncotarget.11807.

[17]GATTI R, BELLETTI S, ORLANDINI G, et al. Comparison of annexin V and calceinAM as early vital markers of apoptosis in adherent cells by confocal laser microscopy[J]. J Histochem Cytochem, 1998, 46(8): 895-900. DOI: 10.1177/002215549804600804.

[18]AKTAS E, KUCUKSEZER U C, BILGIC S, et al.Relationship between CD107a expression and cytotoxic activity[J]. Cell Immunol, 2009;254(2): 149-154. DOI: 10.1016/j.cellimm. 2008.08.007.

[19]GERY S, KOMATSU N, BALDJYAN L, et al.The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells[J]. Mol Cell, 2006,22(3): 375-382. DOI: 10.1016/j.molcel.2006.03.038.

[20]ZENG Z L, LUO H Y, YANG J, et al. Overexpression of the circadian clock gene BMAL1 increases sensitivity to oxaliplatin in colorectal cancer[J]. Clin Cancer Res, 2014, 20(4): 1042-1052. DOI: 10.1158/10780432.CCR130171.

[21]ZHANG F, SUN H, ZHANG S, et al. Overexpression of PER3 inhibits selfrenewal capability and chemoresistance of colorectal cancer stemlike cells via inhibition of notch and βcatenin signaling[J]. Oncol Res, 2017, 25(5): 709-719. DOI: 10.3727/096504016X14772331883976.

[22]PURAM R V, KOWALCZYK M S, DE BOER C G, et al. Core circadian clock genes regulate leukemia stem cells in AML[J]. Cell, 2016, 165(2): 303-316. DOI: 10.1016/j.cell.2016.03.015.

[23]XIA W K, LIU Z L, SHEN D, et al. Prognostic performance of pretreatment NLR and PLR in patients suffering from osteosarcoma[J]. World J Surg Oncol, 2016, 14(1): 1-8. DOI: 10.1186/s1295701608892.

[24]PAHL J H, KWAPPENBERG K M, VARYPATAKI E M, et al.Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferonγ[J]. J Exp Clin Cancer Res, 2014, 33(1): 27. DOI: 10.1186/175699663327.

[25]LABRECQUE N, CERMAKIAN N.Circadian clocks in the immune system[J]. J Biol Rhythms, 2015, 30(4): 277-290. DOI: 10.1177/0748730415577723.

[26]NOBIS C C, DUBEAU LARAME G, KERVEZEE L, et al. The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways[J]. Proc Natl Acad Sci USA, 2019, 116(40): 20077-20086. DOI: 10.1073/pnas.1905080116.

相似文献/References:

[1]胡俊,吴亚光,李露斯,等.高血压伴腔隙性脑梗死患者血压昼夜节律变化的观察[J].第三军医大学学报,2008,30(15):1481.
 HU Jun,WU Ya-guang,LI Lu-si,et al.Circadian rhythm changes of blood pressure in hypertensive patients with lacunar infarct[J].J Third Mil Med Univ,2008,30(18):1481.
[2]刘春燕,钟杭美,罗昭林,等.冠心病心力衰竭患者血压昼夜节律的变化对心率变异性的影响[J].第三军医大学学报,2010,32(12):1371.
[3]张娟,任辉,钟理.原发性高血压患者血压昼夜节律的影响因素分析[J].第三军医大学学报,2010,32(22):2431.
 Zhang Juan,Ren Hui,Zhong Li.Factors influencing circadian rhythm of blood pressure in essential hypertension patients[J].J Third Mil Med Univ,2010,32(18):2431.
[4]王海连.老年高血压病患者血压昼夜节律特点分析[J].第三军医大学学报,2009,31(16):1613.
[5]赵宁波,杨凯,陈丹,等.生物钟PER1基因在口腔鳞癌中的昼夜节律变化及与体内肿瘤生长的关系[J].第三军医大学学报,2013,35(14):1489.
 Zhao Ningbo,Yang Kai,Chen Dan,et al.Circadian rhythm variations of clock gene PER1 expression in oral squamous cell carcinoma and their relations with tumor growth in vivo[J].J Third Mil Med Univ,2013,35(18):1489.
[6]张问德,黎海蒂,罗全生,等.小鼠痛阈和急性低氧耐受性的昼夜节律[J].第三军医大学学报,1991,13(02):0.[doi:10.16016/j.1000-5404.1991.02.035 ]

更新日期/Last Update: 2020-09-22